Publications by authors named "Cheng-Hsiang Chu"
Background: The clinical outcomes of patients with anaplastic lymphoma kinase-positive (ALK+) advanced lung adenocarcinoma vary according to real-world data.
Objective: In this study, we aimed to investigate the treatment discontinuation (TTD) and overall survival (OS) of patients with ALK+ advanced lung adenocarcinoma treated with first-line ALK-TKIs in Taiwan.
Patients And Methods: This retrospective study evaluated all advanced lung adenocarcinoma patients registered in the National Taiwan Cancer Registry from 2017 to 2020 who had ALK rearrangement and received ALK-TKI treatment, using data from Taiwan's National Health Insurance Research Database (NHIRD).
Article Synopsis
- Patients with advanced EGFR-mutant lung adenocarcinoma often develop drug resistance after treating with EGFR-tyrosine kinase inhibitors (TKIs) like osimertinib.
- A study assessed the impact of primary tumor consolidative therapy (PTCT) on progression-free and overall survival among patients who responded to initial osimertinib treatment.
- Results showed that those receiving PTCT had significantly longer progression-free survival (30.3 months vs. 18.2 months) and overall survival, highlighting PTCT as a beneficial treatment option for improving outcomes in this patient group.
Introduction: For patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits.
Methods: This retrospective cohort study was conducted on the database of the National Taiwan Cancer Registry.
We aimed to evaluate whether different driver mutations have varying impacts on the programmed cell death-ligand 1 (PD-L1) expression of non-small cell lung cancer (NSCLC), and whether the prognostic roles of PD-L1 amongst our patients were divergent. This was a single-institute study that included patients with NSCLC. Six driver mutations, PD-L1 status, and the outcomes of treatment were assessed.
View Article and Find Full Text PDF